<?xml version="1.0" encoding="UTF-8"?>
<ref id="B32">
 <label>32</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Leuci</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Casucci</surname>
    <given-names>GM</given-names>
   </name>
   <name>
    <surname>Grignani</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Rotolo</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Rossotti</surname>
    <given-names>U</given-names>
   </name>
   <name>
    <surname>Vigna</surname>
    <given-names>E</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>CD44v6 as innovative sarcoma target for CAR-redirected CIK cells</article-title>. 
  <source>Oncoimmunology</source> (
  <year>2018</year>) 
  <volume>7</volume>(
  <issue>5</issue>):
  <elocation-id>e1423167</elocation-id>. Â 
  <pub-id pub-id-type="doi">10.1080/2162402X.2017.1423167</pub-id>
  <pub-id pub-id-type="pmid">29721373</pub-id>
 </mixed-citation>
</ref>
